<p>Prestige Consumer（纽约证券交易所代码：PBH）将于 2026 年 2 月 5 日（星期四）发布季度财报。以下是投资者在公告前的简要概述。</p>
<p>分析师预计 Prestige Consumer 的 <strong>每股收益</strong>（EPS）为 1.16 美元。</p>
<p>Prestige Consumer 的公告备受期待，投资者希望看到超出预期的消息以及对下个季度的积极指引。</p>
<p>值得新投资者注意的是，指引可能是股价波动的关键因素。</p>
<h3>之前财报的表现</h3>
<p>该公司在上个季度的每股收益超出预期 0.09 美元，导致次日股价下跌 2.3%。</p>
<p>以下是 Prestige Consumer 过去表现及其价格变化的概览：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2026 年第二季度</strong></th>
<th align="right"><strong>2026 年第一季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 预估</strong></td>
<td align="right">0.98</td>
<td align="right">1.00</td>
<td align="right">1.29</td>
<td align="right">1.16</td>
</tr>
<tr>
<td><strong>EPS 实际</strong></td>
<td align="right">1.07</td>
<td align="right">0.95</td>
<td align="right">1.32</td>
<td align="right">1.22</td>
</tr>
<tr>
<td><strong>价格变化 %</strong></td>
<td align="right">-2.00</td>
<td align="right">-3.00</td>
<td align="right">0.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770235267_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770235267_0.png"/></p>
<h3>Prestige Consumer 股价分析</h3>
<p>截至 2 月 3 日，Prestige Consumer 的股票交易价格为 64.43 美元。在过去 52 周内，股价下跌了 23.45%。鉴于这些回报通常为负，长期股东在此次财报发布前可能感到不满。</p>
<h3>分析师对 Prestige Consumer 的观察</h3>
<p>了解市场情绪和行业内的预期对投资者至关重要。本分析深入探讨了 Prestige Consumer 的最新见解。</p>
<p>Prestige Consumer 共收到 2 个分析师评级，普遍评级为买入。平均一年期目标价为 77.0 美元，暗示潜在上涨 19.51%。</p>
<h3>行业同行评级比较</h3>
<p>在此比较中，我们探讨了 Tarsus Pharmaceuticals、Supernus Pharmaceuticals 和 Ligand Pharmaceuticals 这三家知名行业公司的分析师评级和平均一年期目标价，提供对其相对表现预期和市场定位的见解。</p>
<ul>
<li>分析师目前对 Tarsus Pharmaceuticals 的评级为跑赢大盘，平均一年期目标价为 100.0 美元，暗示潜在上涨 55.21%。</li>
<li>分析师目前对 Supernus Pharmaceuticals 的评级为中性，平均一年期目标价为 55.0 美元，暗示潜在下跌 14.64%。</li>
<li>分析师目前对 Ligand Pharmaceuticals 的评级为买入，平均一年期目标价为 242.14 美元，暗示潜在上涨 275.82%。</li>
</ul>
<h3>同行分析总结</h3>
<p>同行分析总结提供了 Tarsus Pharmaceuticals、Supernus Pharmaceuticals 和 Ligand Pharmaceuticals 的关键指标快照，揭示它们在行业中的相对地位。这些指标为其市场地位和比较表现提供了有价值的见解。</p>
<table>
<thead>
<tr>
<th>公司</th>
<th>共识</th>
<th>收入增长</th>
<th>毛利润</th>
<th>股本回报率</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prestige Consumer</td>
<td>买入</td>
<td>-3.41%</td>
<td>1.5158 亿美元</td>
<td>2.29%</td>
</tr>
<tr>
<td>Tarsus Pharmaceuticals</td>
<td>跑赢大盘</td>
<td>146.68%</td>
<td>1.1039 亿美元</td>
<td>-3.77%</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>中性</td>
<td>9.34%</td>
<td>1.7314 亿美元</td>
<td>-4.27%</td>
</tr>
<tr>
<td>Ligand Pharmaceuticals</td>
<td>买入</td>
<td>122.85%</td>
<td>1.1166 亿美元</td>
<td>13.19%</td>
</tr>
</tbody>
</table>
<p>关键要点：</p>
<p>Prestige Consumer 在收入增长和毛利润方面排名靠后，而在股本回报率方面排名中等。</p>
<h3>更好地了解 Prestige Consumer</h3>
<p>Prestige Consumer Healthcare 是最大的纯粹非处方医疗保健提供商之一。它拥有多样化的产品组合，涵盖了细分消费健康类别中的领先品牌。Prestige 的主要品牌包括 Clear Eyes（缓解红眼）、Dramamine（缓解晕动病）、Monistat（阴道抗真菌药）和 Summer's Eve（女性卫生用品），其许多品牌在类别中享有领导地位，并获得医疗专业人士的推荐。该公司主要在北美运营，约 85% 的总收入来自该地区，其余销售来自澳大利亚、新西兰和某些亚洲市场。</p>
<h3>分析 Prestige Consumer 的财务表现</h3>
<p><strong>市值分析：</strong> 公司的市值低于行业基准，反映出与同行相比规模较小。这一定位可能受到增长预期或运营能力等因素的影响。</p>
<p><strong>负面收入趋势：</strong> 对 Prestige Consumer 的财务数据进行三个月的审查显示出挑战。截至 2025 年 9 月 30 日，该公司的收入增长约下降了 <strong>-3.41%</strong>，反映出顶线收益的减少。与同行相比，收入增长落后于行业同行。该公司的增长率低于医疗保健行业同行的平均水平。</p>
<p><strong>净利润率：</strong> Prestige Consumer 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率达到 <strong>15.4%</strong>，展现出强大的盈利能力和有效的成本管理。</p>
<p><strong>股本回报率（ROE）：</strong> 该公司的 ROE 表现突出，超过行业平均水平。其 ROE 达到 <strong>2.29%</strong>，展现出有效利用股本的能力。</p>
<p><strong>资产回报率（ROA）：</strong> 该公司的 ROA 表现突出，超过行业平均水平。其 ROA 达到 <strong>1.23%</strong>，展现出有效利用资产的能力。</p>
<p><strong>债务管理：</strong> 该公司保持平衡的债务管理，债务与股本比率低于行业标准，达到 <strong>0.57</strong>。</p>
<p>要跟踪 Prestige Consumer 的所有财报发布，请访问我们网站的财报日历。</p>
<p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>

普雷斯蒂奇

<p>Prestige Consumer（纽约证券交易所代码：PBH）定于 2026 年 2 月 5 日发布季度财报，分析师预计每股收益（EPS）为 1.16 美元。该公司此前超出每股收益预期 0.09 美元，但股价随后下跌了 2.3%。目前股价为 64.43 美元，Prestige Consumer 的股票在过去一年中下跌了 23.45%。分析师对该股票的评级为 “买入”，一年目标价为 77.0 美元，显示出 19.51% 的潜在上涨空间。该公司在收入增长方面面临挑战，报告显示下降了 3.41%，但保持了 15.4% 的强劲净利润率</p>

<p>Prestige Consumer (NYSE: PBH) will release its quarterly earnings report on Thursday, 2026-02-05. Here's a brief overview for investors ahead of the announcement.</p>
<div class="lb-trans"><p>Prestige Consumer（纽约证券交易所代码：PBH）将于 2026 年 2 月 5 日（星期四）发布季度财报。以下是投资者在公告前的简要概述。</p>
</div><p>Analysts anticipate Prestige Consumer to report an <strong>earnings per share</strong> (EPS) of $1.16.</p>
<div class="lb-trans"><p>分析师预计 Prestige Consumer 的 <strong>每股收益</strong>（EPS）为 1.16 美元。</p>
</div><p>The announcement from Prestige Consumer is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<div class="lb-trans"><p>Prestige Consumer 的公告备受期待，投资者希望看到超出预期的消息以及对下个季度的积极指引。</p>
</div><p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<div class="lb-trans"><p>值得新投资者注意的是，指引可能是股价波动的关键因素。</p>
</div><h3>Performance in Previous Earnings</h3>
<div class="lb-trans"><h3>之前财报的表现</h3>
</div><p>The company's EPS beat by $0.09 in the last quarter, leading to a 2.3% drop in the share price on the following day.</p>
<div class="lb-trans"><p>该公司在上个季度的每股收益超出预期 0.09 美元，导致次日股价下跌 2.3%。</p>
</div><p>Here's a look at Prestige Consumer's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是 Prestige Consumer 过去表现及其价格变化的概览：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2026</strong></th>
<th align="right"><strong>Q1 2026</strong></th>
<th align="right"><strong>Q4 2025</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">0.98</td>
<td align="right">1.00</td>
<td align="right">1.29</td>
<td align="right">1.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">1.07</td>
<td align="right">0.95</td>
<td align="right">1.32</td>
<td align="right">1.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-2.00</td>
<td align="right">-3.00</td>
<td align="right">0.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2026 年第二季度</strong></th>
<th align="right"><strong>2026 年第一季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 预估</strong></td>
<td align="right">0.98</td>
<td align="right">1.00</td>
<td align="right">1.29</td>
<td align="right">1.16</td>
</tr>
<tr>
<td><strong>EPS 实际</strong></td>
<td align="right">1.07</td>
<td align="right">0.95</td>
<td align="right">1.32</td>
<td align="right">1.22</td>
</tr>
<tr>
<td><strong>价格变化 %</strong></td>
<td align="right">-2.00</td>
<td align="right">-3.00</td>
<td align="right">0.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770235267_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2026/1770235267_0.png"/></p>
<h3>Prestige Consumer Share Price Analysis</h3>
<div class="lb-trans"><h3>Prestige Consumer 股价分析</h3>
</div><p>Shares of Prestige Consumer were trading at $64.43 as of February 03. Over the last 52-week period, shares are down 23.45%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.</p>
<div class="lb-trans"><p>截至 2 月 3 日，Prestige Consumer 的股票交易价格为 64.43 美元。在过去 52 周内，股价下跌了 23.45%。鉴于这些回报通常为负，长期股东在此次财报发布前可能感到不满。</p>
</div><h3>Analyst Observations about Prestige Consumer</h3>
<div class="lb-trans"><h3>分析师对 Prestige Consumer 的观察</h3>
</div><p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Prestige Consumer.</p>
<div class="lb-trans"><p>了解市场情绪和行业内的预期对投资者至关重要。本分析深入探讨了 Prestige Consumer 的最新见解。</p>
</div><p>A total of 2 analyst ratings have been received for Prestige Consumer, with the consensus rating being Buy. The average one-year price target stands at $77.0, suggesting a potential 19.51% upside.</p>
<div class="lb-trans"><p>Prestige Consumer 共收到 2 个分析师评级，普遍评级为买入。平均一年期目标价为 77.0 美元，暗示潜在上涨 19.51%。</p>
</div><h3>Comparing Ratings Among Industry Peers</h3>
<div class="lb-trans"><h3>行业同行评级比较</h3>
</div><p>In this comparison, we explore the analyst ratings and average 1-year price targets of Tarsus Pharmaceuticals, Supernus Pharmaceuticals and Ligand Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<div class="lb-trans"><p>在此比较中，我们探讨了 Tarsus Pharmaceuticals、Supernus Pharmaceuticals 和 Ligand Pharmaceuticals 这三家知名行业公司的分析师评级和平均一年期目标价，提供对其相对表现预期和市场定位的见解。</p>
</div><ul>
<li>Analysts currently favor an Outperform trajectory for Tarsus Pharmaceuticals, with an average 1-year price target of $100.0, suggesting a potential 55.21% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Supernus Pharmaceuticals, with an average 1-year price target of $55.0, suggesting a potential 14.64% downside.</li>
<li>Analysts currently favor an Buy trajectory for Ligand Pharmaceuticals, with an average 1-year price target of $242.14, suggesting a potential 275.82% upside.</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师目前对 Tarsus Pharmaceuticals 的评级为跑赢大盘，平均一年期目标价为 100.0 美元，暗示潜在上涨 55.21%。</li>
<li>分析师目前对 Supernus Pharmaceuticals 的评级为中性，平均一年期目标价为 55.0 美元，暗示潜在下跌 14.64%。</li>
<li>分析师目前对 Ligand Pharmaceuticals 的评级为买入，平均一年期目标价为 242.14 美元，暗示潜在上涨 275.82%。</li>
</ul>
</div><h3>Peer Analysis Summary</h3>
<div class="lb-trans"><h3>同行分析总结</h3>
</div><p>The peer analysis summary provides a snapshot of key metrics for Tarsus Pharmaceuticals, Supernus Pharmaceuticals and Ligand Pharmaceuticals, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<div class="lb-trans"><p>同行分析总结提供了 Tarsus Pharmaceuticals、Supernus Pharmaceuticals 和 Ligand Pharmaceuticals 的关键指标快照，揭示它们在行业中的相对地位。这些指标为其市场地位和比较表现提供了有价值的见解。</p>
</div><table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prestige Consumer</td>
<td>Buy</td>
<td>-3.41%</td>
<td>$151.58M</td>
<td>2.29%</td>
</tr>
<tr>
<td>Tarsus Pharmaceuticals</td>
<td>Outperform</td>
<td>146.68%</td>
<td>$110.39M</td>
<td>-3.77%</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>Neutral</td>
<td>9.34%</td>
<td>$173.14M</td>
<td>-4.27%</td>
</tr>
<tr>
<td>Ligand Pharmaceuticals</td>
<td>Buy</td>
<td>122.85%</td>
<td>$111.66M</td>
<td>13.19%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>公司</th>
<th>共识</th>
<th>收入增长</th>
<th>毛利润</th>
<th>股本回报率</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prestige Consumer</td>
<td>买入</td>
<td>-3.41%</td>
<td>1.5158 亿美元</td>
<td>2.29%</td>
</tr>
<tr>
<td>Tarsus Pharmaceuticals</td>
<td>跑赢大盘</td>
<td>146.68%</td>
<td>1.1039 亿美元</td>
<td>-3.77%</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>中性</td>
<td>9.34%</td>
<td>1.7314 亿美元</td>
<td>-4.27%</td>
</tr>
<tr>
<td>Ligand Pharmaceuticals</td>
<td>买入</td>
<td>122.85%</td>
<td>1.1166 亿美元</td>
<td>13.19%</td>
</tr>
</tbody>
</table>
</div><p>Key Takeaway:</p>
<div class="lb-trans"><p>关键要点：</p>
</div><p>Prestige Consumer ranks at the bottom for Revenue Growth and Gross Profit, while it ranks in the middle for Return on Equity.</p>
<div class="lb-trans"><p>Prestige Consumer 在收入增长和毛利润方面排名靠后，而在股本回报率方面排名中等。</p>
</div><h3>Get to Know Prestige Consumer Better</h3>
<div class="lb-trans"><h3>更好地了解 Prestige Consumer</h3>
</div><p>Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare 是最大的纯粹非处方医疗保健提供商之一。它拥有多样化的产品组合，涵盖了细分消费健康类别中的领先品牌。Prestige 的主要品牌包括 Clear Eyes（缓解红眼）、Dramamine（缓解晕动病）、Monistat（阴道抗真菌药）和 Summer's Eve（女性卫生用品），其许多品牌在类别中享有领导地位，并获得医疗专业人士的推荐。该公司主要在北美运营，约 85% 的总收入来自该地区，其余销售来自澳大利亚、新西兰和某些亚洲市场。</p>
</div><h3>Breaking Down Prestige Consumer's Financial Performance</h3>
<div class="lb-trans"><h3>分析 Prestige Consumer 的财务表现</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低于行业基准，反映出与同行相比规模较小。这一定位可能受到增长预期或运营能力等因素的影响。</p>
</div><p><strong>Negative Revenue Trend:</strong> Examining Prestige Consumer's financials over 3 months reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately <strong>-3.41%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>负面收入趋势：</strong> 对 Prestige Consumer 的财务数据进行三个月的审查显示出挑战。截至 2025 年 9 月 30 日，该公司的收入增长约下降了 <strong>-3.41%</strong>，反映出顶线收益的减少。与同行相比，收入增长落后于行业同行。该公司的增长率低于医疗保健行业同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Prestige Consumer's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>15.4%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Prestige Consumer 的财务实力体现在其卓越的净利润率上，超过行业平均水平。该公司的净利润率达到 <strong>15.4%</strong>，展现出强大的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.29%,</strong> the company showcases effective utilization of equity capital.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> 该公司的 ROE 表现突出，超过行业平均水平。其 ROE 达到 <strong>2.29%</strong>，展现出有效利用股本的能力。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.23%,</strong> the company showcases effective utilization of assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> 该公司的 ROA 表现突出，超过行业平均水平。其 ROA 达到 <strong>1.23%</strong>，展现出有效利用资产的能力。</p>
</div><p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.57</strong>.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> 该公司保持平衡的债务管理，债务与股本比率低于行业标准，达到 <strong>0.57</strong>。</p>
</div><p>To track all earnings releases for Prestige Consumer visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟踪 Prestige Consumer 的所有财报发布，请访问我们网站的财报日历。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>
</div>

普雷斯蒂奇品牌的消费者收益：前瞻